Indices of granulocyte activity in inflammatory bowel disease

S. P. KANE, A. V. HOFFBRAND, AND G. NEALE

From the Departments of Medicine and Haematology, Royal Postgraduate Medical School, London

SUMMARY In conditions with increased neutrophil production, the serum total vitamin B₁₂-binding capacity (TBBC) is considered to correlate with the blood pool size of neutrophil granulocytes. The serum lysozyme, on the other hand, is a measure of neutrophil (and monocyte) turnover. The mean serum TBBC was significantly raised in patients with ulcerative colitis (range 1.23-5.51 ng/ml; mean 2.64 ng/ml) and patients with Crohn's disease (range 1.58-9.29 ng/ml; mean 2.93 ng/ml). The elevated values were shown to be due to rises in the granulocyte-secreted binding proteins, transcobalamins I and III. The TBBC was shown to rise with increasing activity of disease and to correlate roughly with the blood neutrophil granulocyte count. Patients with inflammatory bowel disease also had a significantly raised mean level of serum lysozyme (range 3.1-10.4 μg/ml; mean 6.8 μg/ml), but there was no correlation in individual patients between serum lysozyme and total B₁₂-binding capacity. These results are taken to indicate an enlarged granulocyte pool and increased granulocyte turnover in inflammatory bowel disease.

Although it is known that granulocytes cross the mucosa and enter the lumen of the intestine in large numbers in patients with inflammatory bowel disease (Anthonisen and Riis, 1962; Riis and Anthonisen, 1971) their role in the pathological process has received little attention, perhaps because lymphocytes, plasma cells, and histocytes predominate in diseased tissue. Markedly increased numbers of neutrophil leucocytes are rarely found in the circulation of patients with ulcerative colitis or Crohn's disease but they are always present in excess in the inflamed bowel, and crypt abscesses occur frequently in acute ulcerative colitis. In inflammatory conditions, increased granulocyte activity may be associated with high levels of circulating vitamin B₁₂-binding proteins, which rarely lead to elevated serum levels of vitamin B₁₂ (Carmel, 1972a). That a similar situation might exist in patients with inflammatory bowel disease was suggested by our finding of a high serum concentration of vitamin B₁₂ in a patient with ulcerative colitis (serum vitamin B₁₂-2400 pg/ml). Repeated studies in this patient showed a high serum unsaturated vitamin B₁₂-binding capacity ranging from 4.2 to 5.9 ng/ml (normal range: 0.8-1.7 ng/ml). The patient also had a high concentration of serum lysozyme, an enzyme which has been used as a measure of granulocyte turnover (Hansen, 1973). Taken together these findings suggested excess granulocytic activity even though the patient's blood neutrophil granulocyte counts were never excessively high (7000-12 000/cmm³).

In this paper we report a prospective study of vitamin B₁₂-binding proteins and serum lysozyme in an unselected group of patients with inflammatory bowel disease. The study was designed to determine the incidence of high serum levels of vitamin B₁₂-binding proteins and of lysozyme in such patients and to correlate these indices of granulocyte activity with previously established markers of active inflammation.

Patients Studied

Patients with inflammatory bowel diseases

The study was performed on 23 patients with ulcerative colitis and 26 patients with Crohn's disease who were seen consecutively at Hammersmith Hospital by one of us (S.K.). The index case is not included in the results of the prospective study. The diagnosis of inflammatory bowel disease was established on the
basis of the usual clinical, radiological, and histo-
logical criteria. Most patients were studied while on
treatment with sulphasalazine, local or systemic
steroids, or azathioprine. The ages of the patients
ranged from 18 to 84 years. Disease activity was
divided arbitrarily into four grades: (I) complete
absence of symptoms and physical signs; (II) mild
disease controlled on an outpatient basis; (III)
moderate illness requiring inpatient care; (IV) severe
illness with gross systemic upset and incapacitating
diarrhoea.

CONTROL SUBJECTS
Three groups were used: (1) 12 healthy members of
the medical and laboratory staff, aged between 18
and 42 years; (2) 17 patients aged 20-72 years, with
diarrhoea and abdominal pain shown not to be due
to ulcerative colitis or Crohn's disease. (Nine of these
patients had the irritable bowel syndrome, four had
diverticular disease, two had coeliac disease, one had
a salmonella enteritis, and one had a duodenal
diverticulum.) (3) Ten patients aged 18-64 years with
active rheumatoid arthritis.

Materials and Methods
Circulating serum vitamin B\(_{12}\) is bound to three trace
transport proteins, transcobalamins (TC) I, II, and
III, the properties, origins, and significance of which
have recently been reviewed (Zittoun and Zittoun,
1973). Their capacity to bind an excess of added
vitamin B\(_{12}\) \textit{in vitro} is expressed as the serum unsatu-
rated vitamin B\(_{12}\)-binding capacity (UBBC). The
sum of the UBBC and the serum vitamin B\(_{12}\), the
total B\(_{12}\)-binding capacity or TBBC, reflects the sum
of the serum transcobalamin. In seven patients with
raised TBBC values, the relative contributions of the
individual transcobalamin were assessed. For these
studies serum was separated from samples of venous
blood within two hours of venesection and stored at
\(-20°C\) until the time of assay.

SERUM VITAMIN B\(_{12}\)
Vitamin B\(_{12}\) was assayed microbiologically, using the
'z' strain of \textit{Euglena gracilis} (Anderson, 1964)
(normal range 160-925 pg/ml).

SERUM UNSATURATED B\(_{12}\)-BINDING CAPACITY
(UBBC)
The serum UBBC was estimated by a modification of
the rapid charcoal assay originally described by
Gottlieb, Lau, Wasserman, and Herbert (1965). One
ml of a solution of \(^{57}\)Co-B\(_{12}\) (Radiochemical Centre,
Amersham) containing 2400 pg vitamin B\(_{12}\) was
added to 0.5 ml of test serum. The mixture was
incubated for 30 min at room temperature, and
excess free vitamin B\(_{12}\) was removed by incubating
for 10 min with a 2 ml suspension of albumin-coated
charcoal (prepared by mixing equal volumes of a 1%
solution of bovine serum albumin and a 5% aqueous
suspension of Norit A charcoal). After incubation,
the suspension was centrifuged for 10 min at 3000
rpm and 2 ml of the supernatant was counted against
a standard in an automatic gamma counter (Hewlett
Packard). The results were expressed in ng B\(_{12}\)
bound/ml test serum.

SEPARATION OF SERUM B\(_{12}\)-BINDING PROTEINS
The high molecular weight, granulocyte-secreted
binding proteins TC I and TC III were separated
from the lower molecular weight protein (TC II)
by gel filtration using Sephadex G200 (Pharmacia)
under conditions similar to those described by
Bloomfield and Scott (1972). Serum of known UBBC,
0.25-1.0 ml, was incubated for 30 min at room
temperature with enough \(^{57}\)Co-B\(_{12}\) (made up as a
solution containing 2400 pg vitamin B\(_{12}\)/ml) to
saturate fully the binding capacity. The mixture was
then layered onto a Sephadex column (dimensions
60 cm \(\times\) 4 sq cm) and 50 4 ml fractions were eluted
with 0.04 M phosphate in 0.5 M NaCl (containing
sodium azide 0.001 % as a preservative) at the rate of
one fraction every 45 minutes. The radioactivity
of the fractions was determined in an automatic
gamma counter and compared with a known
standard. Thus the binding capacity of each fraction
could be calculated. Transcobalamin I and III were
eluted maximally between fractions 24 and 28, and
TC II between fractions 34 and 38. Excess free
vitamin B\(_{12}\) appeared as a separate peak around
fraction 46.

The batch separation technique of Silverstein and
Herbert (1968) was used to separate unsaturated TC
I from unsaturated TC II and TC III. Serum, 0.25 ml,
was incubated for 30 min with 0.25 ml of a \(^{57}\)Co-B\(_{12}\)
solution containing 12 ng vitamin B\(_{12}\)/ml. This was
then mixed with 0.5 ml albumin-coated charcoal
suspension prepared as described above. After
standing for 10 minutes the mixture was centrifuged
for 10 minutes at 3000 rpm. The supernatant was
decanted and mixed with 170 mg untreated DE 23
cellulose (Whatman) and 2 ml 0.02 M sodium
phosphate buffer, pH 6-3. The mixture was allowed to
stand for 10 minutes after which 5 ml of 0.06 M
sodium phosphate buffer, pH 6-3, was added. The
centrifuge tube was inverted intermittently for 10
min and centrifuged for 10 min at 3000 rpm. The
supernatant was decanted, and a further 5 ml of
0.06 M phosphate buffer was added followed by
further mixing and centrifugation. The two super-
natants, containing the binders eluted at low ionic
strength (TC II and TC III), and the DE 23 pre-
Indices of granulocyte activity in inflammatory bowel disease

57Co-B12 standard

TRANSCOBALAMINS TO 2-8 ng/ml precipitate

OF CONTRIBUTIONS results evaluated and LYSOZYME between TBBC disease (mean arthritis. There controls and bowel diseases inflammatory. Sera from seven patients with a TC I, were counted with a 57Co-B12 standard in an automatic gamma counter.

SERUM LYSOZYME
Serum lysozyme (muramidase) was assayed by the turbidimetric method of Parry, Chandan, and Shahani (1965). In this assay, the rate of decrease of optical density at 37°C of a 2-5 ml suspension of 250 μg/ml UV killed Micrococcus leiosedikicus (Difco) in 0-067 M potassium phosphate buffer, pH 6-2, was measured at 450 nm after adding 0-1 ml of serum. Results were calculated by reference to a standard curve, obtained by assaying graded concentrations of egg-white lysozyme (Sigma).

HAEMOGLOBIN, GRANULOCYTE COUNT, ESR, SERUM ALBUMIN
These estimations were performed using standard haematological and biochemical techniques.

Results

SERUM VITAMIN B12
The normal controls had a mean serum vitamin B12 level of 423 pg/ml (range 160 to 688 pg/ml) whereas the 49 patients with inflammatory bowel diseases had a mean level of 462 pg/ml (range 104-2200 pg/ml). The difference between these two mean levels was not significant (t = 0-6; p > 0-5) nor was there a significant difference in levels between the patients with ulcerative colitis and those with Crohn's disease. Two patients had serum vitamin B12 levels well outside the normal range at 1600 and 2200 pg/ml and only one of the patients had a serum vitamin B12 level below 160 pg/ml.

SERUM TOTAL B12-BINDING CAPACITY
The 49 patients with inflammatory bowel diseases had a mean TBBC of 2-85 ng/ml, while the mean value in the 12 normal subjects was 1-66 ng/ml (fig 1). This difference was highly significant (t = 5-2; p < 0-001). There was no significant difference between the mean TBBC of normal controls and that of patients with either non-inflammatory bowel diseases or with rheumatoid arthritis. There was no significant difference in TBBC between 23 patients with ulcerative colitis (mean 2-64 ng/ml) and 26 patients with Crohn's disease (mean 2-93 ng/ml) (t = 0-77; p > 0-4).

CONTRIBUTIONS OF THE INDIVIDUAL TRANSCOBALAMINS TO THE RAISED TBBC Sera from seven patients with a TBBC of greater than 2-8 ng/ml were fractionated using Sephadex G200, and evaluated by DE 23-cellulose batch separation. The results are shown in the table together with the

![Graph showing TBBC in ng/ml in 12 normal subjects, 49 patients with inflammatory bowel disease, 17 patients with other bowel diseases, and 10 patients with rheumatoid arthritis.](http://gut.bmj.com/)

Table: Serum unsaturated vitamin B12-binding capacities (UBBC) and unsaturated binding capacities of transcobalamin (TC) I, II and III in 10 patients with inflammatory bowel disease

<table>
<thead>
<tr>
<th>Patients</th>
<th>UBBC (ng/ml)</th>
<th>Transcobalamin (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I</td>
<td>II</td>
</tr>
<tr>
<td>B.B.</td>
<td>1.39</td>
<td>0.89</td>
</tr>
<tr>
<td>M.A.</td>
<td>1.47</td>
<td>0.60</td>
</tr>
<tr>
<td>P.G.</td>
<td>1.68</td>
<td>1.30</td>
</tr>
<tr>
<td>S.H.</td>
<td>2.41</td>
<td>1.13</td>
</tr>
<tr>
<td>R.H.</td>
<td>2.84</td>
<td>1.14</td>
</tr>
<tr>
<td>P.P. (Relapse)</td>
<td>3.38</td>
<td>1.50</td>
</tr>
<tr>
<td>P.P. (Remission)</td>
<td>1.45</td>
<td>1.10</td>
</tr>
<tr>
<td>K.H.</td>
<td>3.70</td>
<td>1.94</td>
</tr>
<tr>
<td>M.B.</td>
<td>4.08</td>
<td>1.16</td>
</tr>
<tr>
<td>A.L.</td>
<td>5.26</td>
<td>1.61</td>
</tr>
<tr>
<td>E.C.</td>
<td>9.02</td>
<td>1.03</td>
</tr>
</tbody>
</table>

Normal values: 0.93-1.70 0.33-1.15 0.11-0.62 0.03-0.18 0.08-0.44

The normal range for UBBC is from the present study whilst the ranges of unsaturated binding capacities for the individual transcobalamins is from Bloomfield, Scott, Somerville, and Weir (1973). (Their range for serum UBBC was 0.62-1.34 ng/ml.)
S. P. Kane, A. V. Hoffbrand, and G. Neale

Sephadex G200 fractionation of the sera of three patients whose TBBCs were in the normal range. Representative gel filtration curves are shown in figures 2 and 3. The rise in UBBC and hence in TBBC in patients with inflammatory bowel disease appears to be due largely to a rise in the granulocyte-secreted binders, TC I and TC III, with no significant rise in transcobalamin II. This is exemplified by the study of one patient before and after a remission (fig 3).

Correlation of TBBC with disease activity
Mean values of TBBC increase progressively with disease activity. Asymptomatic patients (grade I) had TBBC levels which did not differ from control values (fig 4). Grade II patients had significantly raised levels compared with grade I patients (0.05 > p > 0.01). The differences between grade II and grade III, and between grade III and grade IV were not statistically significant, but patients with grade III and IV disease together had significantly higher values than those with grade II disease (0.05 > p > 0.01). Moreover, in seven patients studied before and after treatment (fig 5), there was a significant fall in TBBC as the disease remitted (0.02 > p > 0.01).

Fig 2 Sephadex G200 fractionation of 0.5 ml of serum from patient (P.G.) with Crohn's disease (UBBC 1.68 ng/ml), showing the separate peaks of TC I/III, TC II, and free $^{57}$Co-B$_{12}$.

Fig 3 Sephadex G200 fractionation of 0.5 ml of serum from patient (P.P.) with ulcerative colitis in relapse (UBBC 3.38 ng/ml) and in remission (UBBC 1.45 ng/ml).

Fig 4 Serum TBBC in ng/ml in 49 patients with inflammatory bowel disease, six of whom were restudied in remission. Patients were graded I-IV according to clinical severity, and TBBCs contrasted with TBBCs in 12 normal subjects.
Indices of granulocyte activity in inflammatory bowel disease

Correlations were sought between TBBC and recognized indices of disease activity in the patients with inflammatory bowel diseases, but no correlation could be found with haemoglobin concentration \( (n = 29, r = 0.03, p > 0.05) \), serum albumin \( (n = 20, r = 0.33, p > 0.05) \), or ESR \( (n = 26, r = 0.1, p > 0.05) \). There was, however, a just significant correlation between TBBC and circulating granulocyte count \( (n = 27, r = 0.4, p = 0.05) \).

SERUM LYSOZYME
The mean serum lysozyme value in 21 patients with inflammatory bowel disease, 6.8 \( \mu g/ml \), was significantly greater than the mean value of 5.1 \( \mu g/ml \) in 12 normal subjects \( (0.01 > p > 0.001) \) (fig 6). There was no correlation between serum lysozyme levels and TBBC measured on the same sera \( (n = 21, r = 0.30, p > 0.05) \).

AN ATYPICAL B12-BINDING PROTEIN IN A FATHER AND DAUGHTER WITH ULCERATIVE COLITIS
A man with longstanding but inactive ulcerative colitis, not included in the above groups, was noted to have very high levels of TBBC (12.0, 14.8, 27.8 \( \mu g/ml \)) on three occasions in eight months. This rise was entirely due to gross elevation of transcobalamin II. Levels of TC I and TC III were normal as judged by Sephadex G-200 gel filtration. The patient's daughter, also with longstanding but quiescent colitis, had TBBC values of 3.7, 3.7, and 3.4 \( \mu g/ml \). Once again, the rise was due to TC II alone. The cause of these changes, which do not appear to be related to the patients' inflammatory bowel disease, is unknown. Further studies on the nature of their B12-binding proteins will be reported in detail elsewhere (Kane, Hoffbrand, and Neale, 1974, in preparation).

Discussion
These results show that patients with inflammatory bowel disease frequently have raised levels of total serum vitamin B12-binding capacity due primarily to increased concentrations of transcobalamins I and III. While TBBC correlates to some extent with disease activity, rising with increasing severity of illness and falling with remission of disease, it correlates poorly with other established indices of disease activity.
The relationship between raised levels of serum vitamin B₁₂, raised UBBC, and the myeloproliferative disorders (in particular chronic granulocytic leukaemia) has long been recognized (Herbert, 1968; Catovsky, Galton, Griffin, Hoffbrand, and Szur, 1971). These rises were considered to derive largely from increased circulating levels of the α-globulin binder, transcobalamin I. However, in more recent studies it has been shown that TC III also contributes to the raised UBBC levels in chronic granulocytic leukaemia (Bloomfield, Scott, Somerville, and Weir, 1973), and it constitutes the major component of the elevated UBBC found in states of chronic granulocytosis and granulocyte flux (Carmel, 1972a and b). These findings accord with the evidence that both of these vitamin B₁₂-binding proteins are actively secreted by mature granulocytes (Corcino, Krauss, Waxman, and Herbert, 1970; Carmel and Herbert, 1972). Moreover, Chikkappa, Corcino, Greenberg, and Herbert (1971) have shown an excellent correlation between total blood granulocyte pool, measured in vivo by an isotope dilution technique, and both UBBC and total B₁₂-binding capacity. They concluded that measurement of the UBBC may be employed as a simple way of assessing the total blood granulocyte pool. The circulating granulocyte count is dependent upon the distribution of granulocytes and between the circulating marginating components of the pool, and is therefore an unreliable guide to the size of the total pool. Carmel (1972a), while finding increased UBBCs in patients with leucocytosis, found little direct correlation between neutrophil granulocyte counts and UBBC levels. In patients with inflammatory bowel disease, there is only a weak correlation. In chronic granulocytic leukaemia, on the other hand, there is a good correlation between granulocyte counts and TBBC (Catovsky et al, 1971). It seems that many patients with inflammatory bowel disease, particularly those with more active disease, have an expanded body pool of granulocytes, a feature which is not found in a miscellaneous collection of other bowel diseases, nor in rheumatoid arthritis, a chronic inflammatory process not involving the bowel. The site of this pool is, therefore, likely to be the bowel wall itself.

The serum vitamin B₁₂ was normal in nearly all of our patients. This is similar to the finding of Carmel (1972a) in patients with benign granulocytosis and a raised TBBC, and contrasts with the usual finding in myeloproliferative diseases in which the serum vitamin B₁₂ itself is often raised. The explanation for the difference is uncertain, but it may be that the increased TBBC in inflammation is predominantly in TC III and not in TC I as in the myeloproliferative diseases. A raised serum vitamin B₁₂ seems to be found more commonly when there is a rise in transcobalamin I rather than transcobalamin III. It is of interest that in one of the patients who initially had a high serum vitamin B₁₂ level of 920 pg/ml (TBBC 5-01 ng/ml) the serum vitamin B₁₂ level fell to 160 pg/ml (TBBC 1-56 ng/ml) four months after starting treatment with azathioprine. In such a patient a high concentration of vitamin B₁₂-binding proteins might mask vitamin B₁₂ deficiency as had been described in patients with chronic granulocytic leukaemia and concomitant pernicious anaemia (Britt and Rose, 1966; Corcino, Zalusky, Greenberg, and Herbert, 1971).

The raised levels of serum lysozyme may indicate an increased granulocyte turnover rate in patients with inflammatory bowel disease. Lysozyme appears to be released from dying granulocytes (Fink and Finch, 1968) and serum values have been shown by some workers (Hansen, 1973) but not by others (Levi, MacQueen, and Vincent, 1973) to correlate with granulocyte turnover rate in man. Other factors have to be considered. Serum lysozyme is raised in gross vitamin B₁₂ or folate deficiency with megaloblastic anaemia probably due to ineffective leucopoiesis (Perillie, Kaplan, and Finch, 1967). In the present study none of the patients with raised lysozyme levels had a megaloblastic anaemia. Lysozyme is also released from monocytes and raised lysozyme levels have been noted in acute monocytic leukaemia (Osserman and Lawlor, 1966; Catovsky et al, 1971) and in active sarcoidosis (Pascual, Gee, and Finch, 1973). Thus, it is possible that excess lysozyme is released from monocytes in patients with inflammatory bowel disease. Monocytes are also known to secrete small amounts of TC I (Carmel and Coltman, 1971) but do not normally make a significant contribution to the serum UBBC (Chikkappa et al, 1971).

Whether granulocytes play an important primary role in the inflammatory process of Crohn’s disease and ulcerative colitis or accumulate secondary to damage to the bowel by other processes remains uncertain. The present findings show, however, that the activity of the disease may be monitored by measurements of indices of granulocyte activity, the serum TBBC and serum lysozyme.

We should like to thank Mr J. Tillera for technical assistance, and Miss Aviva Petrie for statistical advice.

References


Indices of granulocyte activity in inflammatory bowel disease


Indices of granulocyte activity in inflammatory bowel disease

S. P. Kane, A. V. Hoffbrand and G. Neale

Gut 1974 15: 953-959
doi: 10.1136/gut.15.12.953

Updated information and services can be found at:
http://gut.bmj.com/content/15/12/953

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/